A Radical Simplification of Genomic Medicine
What if a patient’s genome could be sequenced once, at any point in their healthcare journey, and then reanalysed throughout their lifetime as new clinical questions arise? This is the core premise of Singapore’s SOAR model—Sequence Once, Analyse Repeatedly—and it underpins Phase III of the National Precision Medicine programme, known as SG-INSIGHT.
The Scale of Ambition
Phase III, launched in November 2025, aims to generate whole genome sequences for approximately 10% of Singapore’s resident population—roughly 450,000 people. Unlike Phase II, which focused on population cohorts, Phase III enrols patients receiving medical care across all three public healthcare clusters: NHG Health, NUHS, and SingHealth.
This shift matters. By studying patients with active health conditions, the programme addresses the full healthcare life course—from early to late-stage disease—in real-world clinical settings where comorbidities, cost pressures, and treatment decisions converge.
Why Economics Are Shifting
Falling costs of genetic sequencing and information technology have made the SOAR model economically viable for the first time. When a genome costs less than a single MRI, the calculus of clinical genomics changes fundamentally. Phase III will test whether universal whole-genome sequencing—analysed as needed rather than exhaustively upfront—can deliver better outcomes at sustainable cost.
Genomic Innovation Hubs
To translate sequencing into clinical action, Phase III is establishing Genomic Innovation Hubs within each healthcare cluster. These hubs will identify genetic conditions suitable for eventual mainstreaming into routine care. The initial focus is pharmacogenomics, with expansion to other use cases as evidence accumulates.
Real-World Utility Testing
Phase III is explicitly designed to demonstrate large-scale whole genome sequencing clinical utility. This means measuring not just whether sequencing identifies variants, but whether those findings change clinical decisions and improve patient outcomes. The programme will also enrich the PRECISE-SG100K resource with new multi-omic, imaging, and digital phenotyping data, creating a progressively deeper foundation for AI-driven discovery.
A Community of Participants
Crucially, Phase III builds a community of engaged patient participants who actively contribute to genomic research and healthcare innovation. This participatory model distinguishes Singapore’s approach from extractive research paradigms—participants are partners, not specimens.
